


## Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R<sup>1</sup> represents hydrogen, -C<sub>1-6</sub> alkyl, -C<sub>0-4</sub> alkyl-C<sub>3-8</sub>cycloalkyl, -C<sub>2-4</sub> alkoxy-C<sub>1-4</sub> alkyl, -C<sub>1-4</sub> alkyl-aryl, -C<sub>1-4</sub> alkyl-heteroaryl or -C<sub>0-4</sub> alkyl-heterocyclyl, or R<sup>1</sup> is linked to R<sup>2</sup> to form a group (CH<sub>2</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub> or (CH<sub>2</sub>)<sub>4</sub>;

wherein said alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl groups of R<sup>1</sup> may be optionally substituted by one or more (e.g. 1, 2 or 3) halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, cyano, amino or trifluoromethyl groups;

R<sup>2</sup> represents hydrogen or C<sub>1-6</sub> alkyl;

m represents an integer from 1 to 4, such that when m is an integer greater than 1, two R<sup>2</sup> groups may instead be linked to form a CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub> group;

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen, halogen, cyano, -CF<sub>3</sub>, -CF<sub>3</sub>O, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl or a group -CONR<sup>6</sup>R<sup>7</sup>;

R<sup>6</sup> and R<sup>7</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;

n represents an integer from 1 to 3;

p represents 1 or 2;

J represents CH<sub>2</sub>, CO, CF<sub>2</sub>, CH(OR<sup>8</sup>), NR<sup>9</sup>, SO, O or S;

R<sup>8</sup> and R<sup>9</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl;

A represents an -aryl, -heteroaryl, -aryl-aryl, -aryl-heteroaryl, -heteroaryl-aryl or -heteroaryl-heteroaryl group;

wherein said aryl and heteroaryl groups of A may be optionally substituted by one or more (e.g. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C<sub>1-6</sub> alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C<sub>1-6</sub> alkoxy, arylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkoxycarbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-6</sub> alkyl, C<sub>1-6</sub>

alkylsulfonamido, C<sub>1-6</sub> alkylamido, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC<sub>1-6</sub> alkyl, arylcarboxamidoC<sub>1-6</sub> alkyl, aroyl, aroylC<sub>1-6</sub> alkyl, arylC<sub>1-6</sub> alkanoyl, or a group CONR<sup>10</sup>R<sup>11</sup> or SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, wherein R<sup>10</sup> and R<sup>11</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or R<sup>10</sup> and R<sup>11</sup>

- 5 together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;  
or solvates thereof.
2. A compound of formula (I) as defined in claim 1 which is:  
10 3-[(3-Chlorophenyl)methyl]-8-(1-piperazinyl)quinoline;  
(3-Chlorophenyl)[8-(1-piperazinyl)-3-quinoliny]methanone;  
3-(Phenyloxy)-8-(1-piperazinyl)quinoline;  
or a pharmaceutically acceptable salt thereof.
- 15 3. A pharmaceutical composition which comprises a compound as defined in claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.
4. A compound as defined in claim 1 or claim 2 for use in therapy.
- 20 5. A compound as defined in claim 1 or claim 2 for use in the treatment of depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.
- 25 6. The use of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.
- 30 7. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 2 for use in the treatment of depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.
- 35 8. A method of treating depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.